secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001193125-26-001495
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics appoints Sung H. Lee to Board; grants option for 60k shares at $8.93
--------------------------------------------------------------------------------

- Board expanded to 8; Lee appointed as Class I director, term until 2028 annual meeting.
- Lee to receive stock option for 60,000 shares at $8.93, vesting monthly over 3 years.
- Lee to receive RSU for 10,000 shares vesting annually over 3 years; $40k annual retainer.
- Lee is EVP & CFO at Cytokinetics, previously CFO at Vir, MorphoSys, Sangamo; 20+ yrs finance experience.
- CEO says Lee's expertise will support lead program vopimetostat in registrational studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526001495/0001193125-26-001495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526001495/d44532d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-001495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer